Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria

Chronic spontaneous urticaria (CSU) affects approximately 1–2% of the world's population, and lasts for 5 years or more in 45–70% of patients. 1 Gonçalo M Gimenéz-Arnau A Al-Ahmad M et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021; 184: 226-236 Crossref PubMed Scopus (124) Google Scholar Because of the unpredictable occurrence of wheals or angioedema, as well as severe pruritus, CSU is associated with sleep disturbance, reduced quality of life, strained relationships, absenteeism from work or school, and mental health comorbidities. 1 Gonçalo M Gimenéz-Arnau A Al-Ahmad M et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021; 184: 226-236 Crossref PubMed Scopus (124) Google Scholar Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trialsIn the phase 3 PEARL studies, ligelizumab demonstrated superior efficacy versus placebo but not versus omalizumab. The safety profile of ligelizumab was consistent with previous studies. Full-Text PDF